Mesalamine
Administration
- Type: Anti-inflammatory
- Dosage Forms: TAB 800mg, 1.2g
- Routes of Administration: Oral
- Common Trade Names: Apriso, Asacol, Asacol HD, Delzicol, Lialda, Pentasa
Adult Dosing
Ulcerative Colitis
- Mild-Moderate Active
- 2.4-4.8g PO qd x 8 weeks
- Moderate Active
- 1600 mg PO tid x 6 weeks
- Maintenance tx
- 2.4 g PO qd
Pediatric Dosing
- Currently unavailable
Special Populations
- Pregnancy Rating: C
- Lactation risk: Caution advised.
Renal Dosing
- Adult: Not defined
- Pediatric: Not defined
Hepatic Dosing
- Adult: Not defined
- Pediatric: Not defined
Contraindications
- Allergy to class/drug
- Influenza, varicella, or febrile infection in pts <20 yo
Adverse Reactions
Serious
- Acute intolerance syndrome
- Hypersensitivity reaction
- Anaphylaxis
- Angioedema
- Stevens-Johnson syndrome
- Nephropathy, interstitial nephritis, renal failure
- Hepatotoxicity, hepatic failure
- Pericarditis, myocarditis, pneumonitis
- Agranulocytosis, aplastic anemia
- Pancreatitis
Common
- Headache
- Flatulence
- Nausea
- AST, ALT elevation
- Abdominal pain
Pharmacology
- Half-life: 2-15h (tid dosing) and 7-12h (qd dosing)
- Metabolism: GI tract, liver
- Excretion: Urine, feces
Mechanism of Action
- Blocks cyclooxygenase and inhibits prostaglandin production in the colon, exerting local anti-inflammatory effects
